Gilead Pulls Trodelvy’s Accelerated Approval
Recently, Gilead Sciences, Inc. announced a significant decision regarding its immunotherapy drug, Trodelvy, known chemically as sacituzumab govitecan-hziy. The company has chosen to voluntarily withdraw the U.S. accelerated approval for Trodelvy as a treatment for adult patients suffering from advanced or metastatic urothelial cancer. This decision comes after the drug did not meet expectations in the pivotal Phase 3 TROPiCS-04 study, which was intended to verify the drug's clinical benefits.
Details of the TROPiCS-04 Study
The TROPiCS-04 study aimed to assess Trodelvy in comparison to single-agent chemotherapy for patients whose cancer had spread despite previous treatments with platinum-containing chemotherapy and PD-1 inhibitors.
Study Findings
Unfortunately, the results indicated that Trodelvy failed to demonstrate improved overall survival in the trial's intention-to-treat population. Such outcomes led Gilead to consult closely with the FDA before making the official decision to withdraw the prior approval for this specific indication. This withdrawal, however, does not impact Trodelvy's other approved uses.
Trodelvy’s Approval History
Trodelvy first gained accelerated approval in 2021, based on favorable data from the earlier TROPHY-U-01 study, which showcased promising tumor response rates. Continuous approval was contingent on further clinical validation, which was expected from the confirmatory TROPiCS-04 study.
The Impact of Current Trials
Despite this setback, Trodelvy remains a critical part of Gilead's efforts in oncology. The drug is recognized as the first FDA-approved Trop-2-directed antibody-drug conjugate (ADC), which has shown potential in improving survival rates in metastatic triple-negative breast cancer and other cancers.
Ongoing Research and Future Prospects
Currently, numerous clinical trials are underway to evaluate Trodelvy both as a standalone treatment and in combination with other therapies targeting a wide array of solid tumors, including lung cancer and gynecological cancers. Notably, Trodelvy is a participant in the EVOKE-03 trial, which is investigating its effectiveness in combination with Merck & Co., Inc.'s Keytruda (pembrolizumab) for patients with PD-L1-high metastatic non-small cell lung cancer. This trial commenced in early 2023 and is projected to complete by January 2027.
Market Reaction to the Announcement
Following the announcement of the withdrawal, market reactions were observable, with Gilead’s stock showing a slight decline of 0.67%, settling at $86.78. Investors are keenly watching the unfolding developments as Gilead navigates this challenging situation.
Looking Ahead for Gilead
As Gilead Sciences moves forward, it continues to focus on the broader potential of Trodelvy. With a robust pipeline and ongoing clinical research, the company is committed to exploring innovative solutions for patients battling various forms of cancer. Gilead's leadership remains optimistic about the future and is determined to deliver meaningful advancements in cancer care.
Frequently Asked Questions
What prompted Gilead to withdraw the Trodelvy approval?
Gilead withdrew the approval after the confirmatory TROPiCS-04 study failed to meet its primary endpoint of improved overall survival.
Is Trodelvy still available for other types of cancer?
Yes, Gilead continues to offer Trodelvy for other approved indications that are unaffected by this withdrawal.
What other treatments does Gilead offer?
Gilead has a diverse portfolio, including treatments for viral infections, inflammatory diseases, and various cancers, continually advancing its research and development.
How does Trodelvy work?
Trodelvy functions as a Trop-2-directed antibody-drug conjugate, aiming to target cancer cells directly while minimizing impact on healthy cells.
What are the current trials involving Trodelvy?
Trodelvy is being investigated in multiple clinical trials, including the EVOKE-03 trial alongside Merck's Keytruda for non-small cell lung cancer.
